FORMATO EUROPEO PER IL CURRICULUM VITAE...ricerca di circa 40 studi clinici negli ultimi anni....

Pagina 1 – Sebastiano Filetti

Informazioni personali

Nome / Cognome SEBASTIANO FILETTI

Dipartimento

Medicina Interna e Specialità Mediche

Università di Roma- Azienda Policlinico Umberto I- Viale del Policlinico,155 00161 Roma

Settore Scientifico-Disciplinare MED/09 Medicina Interna

Indirizzo Azienda Ospedaliera Universitaria- Policlinico Umberto I

Viale del Policlinico, 155 - 00161 Roma

E-mail

Telefono

[email protected]

[email protected]

Codice Fiscale FLTSST49E13C351G

06 4997.5130

Fax 06 4997.8372

Attuale Posizione Professore Ordinario di Medicina Interna presso la Facoltà di Medicina e Chirurgia dell'Università degli

Studi di Roma "Sapienza

Direttore DAI di Medicina Interna e Specialità Mediche. Azienda ospedaliero-universitaria policlinico

Umberto I

Dirigente Medico di II livello responsabile U.O.C. di Medicina Interna e Malattie Metaboliche – Azienda

Policlinico Umberto I - Roma

Delegato del Rettore per i “Rapporti internazionali area sanitaria”- biennio 2018-2020

Editor in Chief “Endocrine-Springer dal 2018-

Preside della Facoltà di Medicina e Odontoiatria dell'Università degli Studi di Roma "Sapienza"2015 –

2018“

Componente Commissione Tecnico-scientifica dell’AIFA (Agenzia Italiana del Farmaco), 2015-2018

Coordinatore Dottorato di Ricerca “Tecnologie biomediche in Medicina Clinica” (cod. 11124)” Università

degli Studi di Roma "Sapienza" dal 2007

Coordinatore della Scuola di Specializzazione in Medicina Interna dell’Università degli Studi di Roma

"Sapienza" dal 2009 a ottobre 2017

Coordinatore Tronco comune Scuole di Specializzazione di Area Medica “Sapienza” Università di Roma

Docente presso le Scuole di Specializzazione dell’Università degli Studi di Roma "Sapienza": Scuola di

Specializzazione in Medicina Interna; Scuola di Specializzazione in Endocrinologia e Malattie del Ricambio;

Scuola di Specializzazione in Gastroenterologia dal 2007-2015

mailto:[email protected]:[email protected]


Formazione Professore Ordinario di Medicina Interna, Università di Roma “Sapienza” dal 2001 ad oggi

Presidente del Corso di Laurea Magistrale in Medicina e Chirurgia “A”, Sapienza Università di Roma dal

2010 a Novembre 2015

Professore Ordinario di Medicina Interna, Università di Catanzaro dal 1997 - 2001

Professore Ordinario di Endocrinologia, Università di Catanzaro, 1994-97

Professore Associato di Endocrinologia, Università di Reggio Calabria, Catanzaro 1987-1993

Ricercatore in Patologia Medica, Università di Catania, 1980-1987

Specializzazione in Endocrinologia, Catania, luglio 1975

Laurea in Medicina e Chirurgia, Catania, 30 novembre 1973

Madrelingua Italiano

Other language(s) UNDERSTANDING SPEAKING WRITING

Listening Reading

Spoken

interaction

Spoken

production

Inglese C1 C1 C1 C1 C1 Francese C1 C1 C1 C1 C1

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user

Common European Framework of Reference for Languages

Premi:

1979 Grant Fullbright-Hays

1979 Premio della Società Italiana di Diabetologia

1984 Premio della Società Italiana di Endocrinologia

1997 Premio della Società Italiana di Endocrinologia

Società scientifiche:

Endocrine Society, American Thyroid Association, American Diabetes Association, Società di Medicina

Interna, Società Italiana di Endocrinologia, Società Italiana di Diabetologia,

Altre capacità e competenze Editor in Chief “ENDOCRINE” Springer dal 2018-

Associate Editor della rivista “Endocrine”, Spronger, N.Y.dal 2014-2018

Associate Editor di Orphanet Journal of Rare Diseases dal 2009-2017

Consiglio Scientifico dell’EFEC (Ecole de Formation Européenne en Cancérologie)dal 2003-2012

Editorial Board di “The Journal of Clinical Endocrinology and Metabolism” dal 2004-2009

Esperienze in laboratori esteri:

1 anno a Bruxelles (Belgio), 1 anno a Londra (Gran Bretagna), 5 anni presso l’Università della California,

San Francisco (USA).

In atto collabora con il Department of Endocrine Neoplasia & Hormonal Disorders, M.D. Anderson,

University of Texas, Houston, USA e con L'Istituto Tumori Gustave-Roussy, Parigi

esperienza di ricerca in metabolismo ed endocrinologia cellulare/molecolare e clinica.


Sperimentazioni Cliniche:

Il Professor Sebastiano Filetti ha maturato esperienza clinica in qualità di responsabile di U.O.C. di

Medicina Interna dal 1994 ad oggi. Ha partecipato a numerosi trials clinici, ed è stato responsabile di

ricerca di circa 40 studi clinici negli ultimi anni. (Phase II, Phase III) fino al 30/08/2015.

Brief Summary of Relevant Clinical Research Experience:

06 trials in the cardiovascular field

10 trials in metabolism/dyslipidemia

05 endocrine oncology and thyroid cancer

18 trials in Type II Diabetes

GCP training at investigators meeting for these studies

Amgen. ClinicalTrials.gov:

NCT00121628

2004 2005 A Phase 2, Open-Label Study of AMG 706 to Treat

Subjects with Locally Advanced or Metastatic Thyroid

Cancer who are not Candidate for Radioactive Iodine

Therapy

AstraZeneca.

ClinicalTrials.gov:

NCT0041076. Study ID

Number: D4200C00058

2006

2015*

An International, Phase III, Randomized, Double-Blinded,

Placebo-Controlled, Multi-Center Study to Assess the

Efficacy of ZD6474 (ZACTIMA) Versus Placebo in

Subjects With Unresectable Locally Advanced or

Metastatic Medullary Thyroid Cancer

Novo Nordisk.

ClinicalTrials.gov:


Number: NN2211-1860 NN2211-1860 -NN2211-1860

2008 2009 The Effect of Liraglutide Compared to Sitagliptin, Both in

Combination With Metformin in Subjects With Type 2

Diabetes. A 26-week, Randomised, Open-label, Active

Comparator, Three-armed, Parallel-group, Multi-centre,

Multinational Trial With a 52-week Extension

AstraZeneca.

ClinicalTrials.gov:


Number: D1690C00004

2008 2010 A 52-Week International, Multi-centre, Randomised,

Parallel-group, Double-blind, Active-controlled, Phase III

Study With a 156-Week Extension Period to Evaluate the

Efficacy and Safety of Dapagliflozin in Combination With

Metformin Compared With Sulphonylurea in Combination

With Metformin in Adult Patients With Type 2 Diabetes

Who Have Inadequate Glycaemic Control on Metformin

Therapy Alone

Bayer. ClinicalTrials.gov:


Number: 12198

2008 2015*

A Randomized, Double-Blind, Placebo-Controlled, Multi-

Center, Parallel Group Study to Assess the Efficacy

(Reduction of Cardiovascular Disease Events) and Safety

of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients

at Moderate Risk of Cardiovascular Disease

Novartis.

ClinicalTrials.gov:


Number: CSPP100E2337

2008 2015*

A Randomized, Double-blind, Placebo-controlled, Parallel

Group Study to Determine Whether, in Patients With Type

2 Diabetes at High Risk for Cardiovascular and Renal

Events, Aliskiren, on Top of Conventional Treatment,

Reduces Cardiovascular and Renal Morbidity and

Mortality

Merck Sharp & Dohme.

ClinicalTrials.gov:


Number: 0431-102

2009 2010 A Multicenter, Randomized, Double-Blind Study of the Co-

Administration of Sitagliptin and Pioglitazone in Patients

With Type 2 Diabetes Mellitus Who Have Inadequate

Glycemic Control

Novartis.

ClinicalTrials.gov:


Number: CLAF237B2224

2009

2011

A Multi-Center, Randomized, Double-Blind Study to

Evaluate the Efficacy and Long-Term Safety of Vildagliptin

Modified Relase (MR) as Add-on Therapy to Metformin in

Patients With Type 2 Diabetes

Bayer. Chairman Data

Monitoring.

ClinicalTrials.gov:


Number: 14295

2009

2013

A Double-Blind Randomized Phase III Study Evaluating

the Efficacy and Safety of Sorafenib Compared to Placebo

in Locally Advanced/Metastatic RAI-Refractory

Differentiated Thyroid Cancer

EISAI. ClinicalTrials.gov:


Number: E7080-G000-201

2009 2014 A Phase II, Multicenter, Open Label, Single Arm Trial to

Evaluate the Safety and Efficacy of Oral E7080 in

Medullary and Iodine-131 Refractory, Unresectable

Differentiated Thyroid Cancers, Stratified by Histology


Exelixis. ClinicalTrials.gov: NCT00704730. Study ID

Number: XL184-301

2009

2014

An International, Randomized, Double-Blinded, Phase 3

Efficacy Study of XL184 versus Placebo in Subjects with

Unresectable, Locally Advanced, or Metastatic Medullary

Thyroid Cancer

Novo Nordisk.

ClinicalTrials.gov:


Number: NN1250-3582

2010

2011

NN1250-3582: A 52-week Randomised, Controlled, Open

Label, Multicentre, Multinational Treat-to-target Trial

Comparing Efficacy and Safety of SIBA and Insulin

Glargine Both Administered Once Daily in a Basal-bolus

Regimen With Insulin Aspart as Mealtime Insulin ±

Treatment With Metformin, ± Pioglitazone in Subjects With

Type 2 Diabetes Currently Treated With Insulin Qualifying

for Intensified Treatment (BEGIN™: BB)

Novo Nordisk.

ClinicalTrials.gov:


Number: NN1250-3667

2011 2011 NN1250-3667: An Extension Trial to NN1250-3582

Comparing Safety and Efficacy of NN1250 and Insulin

Glargine, Both With Insulin Aspart as Meal-time Insulin ±

OADs in Type 2 Diabetes (BEGIN™: BB)

AstraZeneca/Eli Lilly.

ClinicalTrials.gov:.


Number: H8O-IT-B014

2010

2012

EBIRIOS - Exenatide and Basal Insulins Use in the Real

Setting: an Italian Observational Study in Patients With

Type 2 Diabetes and Secondary Failure of Oral

Antihyperglycemic Treatment

EISAI. ClinicalTrials.gov:


Number: E7080-G000-303

2010

2015* A Multicenter, Randomized, Double-Blind, Placebo-

Controlled, Phase 3 Trial of E7080 in 131I-Refractory

Differentiated Thyroid Cancer

Novo Nordisk.

ClinicalTrials.gov:


Number: EX2211-3748

2010

2015*

A Long-term, Multi-centre, International, Randomised

Double-blind, Placebo-controlled Trial to Determine

Liraglutide Effects on Cardiovascular Events

AstraZeneca.

ClinicalTrials.gov:


Number: D4200C00088

2011

2014 A Randomized, International, Open-Label, Multi-Centre,

Phase III Study to Assess the Effect of a Patient Outreach

Program on the Percentage of Time Patients with Locally

Advanced or Metastatic Medullary Thyroid Cancer

Experience Grade 2 or Higher Adverse Events during the

First 12 Months of Treatment with Vandetanib

Medtronic.

ClinicalTrials.gov:


Number: EUR05/CEP234

2011

2015*

OpT2mise Glucose Control in Type 2 DM With Insulin

Pump Therapy


ClinicalTrials.gov:


Number: 0431-403

2011

2015* A Phase III, Multicenter, Randomized, Open-label Clinical

Trial Comparing the Efficacy and Safety of a Sitagliptin-

Based Treatment Paradigm to a Liraglutide-Based

Treatment Paradigm in Patients With Type 2 Diabetes

Mellitus Who Have Inadequate Glycemic Control on

Metformin Monotherapy


ClinicalTrials.gov:


Number: 0431-260

2012

2015* A Phase III, Multicenter, Randomized, Double-Blind,

Placebo-Controlled Clinical Trial to Study the Safety and

Insulin-Sparing Efficacy of the Addition of Sitagliptin in

Patients With Type 2 Diabetes Mellitus Who Have

Inadequate Glycemic Control on Insulin Alone or in

Combination With Metformin

Novartis.

ClinicalTrials.gov:


Number: CLAF237A23156

2012

2015* A 5-year Study to Compare the Durability of Glycemic

Control of a Combination Regimen With Vildagliptin &

Metformin Versus Standard-of-care Monotherapy With

Metformin, Initiated in Treatment-naïve Patients With Type

2 Diabetes Mellitus

Novo Nordisk.

ClinicalTrials.gov:


Number: NN1250-3944

2012

2015* The Effect of Insulin Degludec in Combination With

Liraglutide and Metformin in Subjects With Type 2

Diabetes Qualifying for Treatment Intensification

AstraZeneca.

ClinicalTrials.gov:


Number: D4200C00097

2012 2015 An International, Randomised, Double-Blind, Two-Arm

Study to Evaluate the Safety and Efficacy of Vandetanib

150 and 300 mg/day in Patients with Unresectable Locally

Advanced or Metastatic Medullary Thyroid Carcinoma with

Progressive or Symptomatic Disease


ClinicalTrials.gov:


Number: 3102-018

2013 2015* A Randomized, Double-blind, Placebo-controlled,

Multicenter Study to Assess Cardiovascular Outcomes

Following Treatment With MK-3102 in Subjects With Type

2 Diabetes Mellitus


EXPERIENCE IN SELECTED

CLINICAL TRIALS

AstraZeneca.

ClinicalTrials.gov:


Number: D4203C00011

2013 2015* A Randomized, Double-Blind, Placebo-Controlled, Multi-

Centre Phase III Study to Assess the Efficacy and Safety

of Vandetanib (CAPRELSA™; SAR390530 (Formerly

AstraZeneca ZD6474)) 300 mg in Patients With

Differentiated Thyroid Cancer That Is Either Locally

Advanced or Metastatic Who Are Refractory or Unsuitable

for Radioiodine (RAI) Therapy

AstraZeneca.

ClinicalTrials.gov:


Number: D1532C00065

2013 2015* A Randomised, Double Blind Study to Compare the

Complete Remission Rate Following a 5-Week Course of

Selumetinib or Placebo and Single Dose Adjuvant

Radioactive Iodine Therapy in Patients With Differentiated

Thyroid Cancer

Novo Nordisk.

ClinicalTrials.gov:


Number: NN9535-3624

2013 2015* Efficacy and Safety of Semaglutide Once-weekly Versus

Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral

Antidiabetic Drugs (OADs) in Subjects With Type 2

Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)

Novo Nordisk.

ClinicalTrials.gov:


Number: NN9924-3790

2013 2014 Multiple Dose Trial Examining Dose Range, Escalation

and Efficacy of Oral Semaglutide in Subjects With Type 2

Diabetes

Novo Nordisk.

ClinicalTrials.gov:


Number: EX1250-4080

2014 2015* A Trial Comparing Cardiovascular Safety of Insulin

Degludec Versus Insulin Glargine in Subjects With Type 2

Diabetes at High Risk of Cardiovascular Events

*From September 1st, 2015, Sebastiano Filetti left the position of Principal Investigator of these Clinical Trials due to

a concomitant appointment as a member of the AIFA (Italian Drugs Agency) Technical-Scientific Committee.

Please note: all these Clinical Trials included a GCP training

*


BOOK CHAPTERS:

1. “Non toxic goiter and thyroid neoplasia” pubblicato nel volume Williams Textbook of

Endocrinology – 13th Edition 2015, Editors: Larsen, Kronenberg, Melmed, Polonsky,

Saunders Publisher

2. Sebastiano Filetti, Cosimo Durante, Clark/Duh Radioactive Iodine Therapy: Mechanisms

and Indications : Endocrine Surgery textbook JP Brothers Medical Publishers, 2015

3. Maria Chiara Zatelli, Efisio Puxeddu, Elisa Menicali, Ettore degli Uberti, and Sebastiano Filetti

Molecular Markers in Thyroid Fine-Needle Aspiration Biopsies Springer International

Publishing Switzerland 2015 C.P. Lombardi, R. Bellantone (eds.), Minimally Invasive Therapies

for Endocrine Neck Diseases

4. S. Filetti, R. Michael Tuttle, Steven I. Sherman Medical Management of differentiated

epithelial cell thyroid cancer pubblicato nel volume “Werner & Ingbar’s the Thyroid, a

Fundamental and Clinical Text” Editors: Braverman L, Cooper DS. , 10th Edition. Philadelphia,

Lippincott Williams & Wilkins, 2013. Chapter 50E, pag. 725-743.

5. “Non toxic goiter and thyroid neoplasia” pubblicato nel volume Williams Textbook of

Endocrinology – 12thEdition 2011, chapter 14, Editors: Larsen, Kronenberg, Melmed,

Polonsky, Saunders Publisher

6. “Carcinoma midollare della tiroide: genetica e diagnostica molecolare” pubblicato nel

volume LaTiroide, Fisiopatologia, diagnostica molecolare – clinica e terapia, 2004, Editor:

Andreoli, Il Pensiero Scientifico Publisher

7. “L’Algoritmo diagnostico” pubblicato nel volume Tiroide, diagnostica per immagini e

approccio clinico ragionato, Editors: Lagalla, Attard, Latteri, Midiri, Idelson-Gnocchi

Publisher 2004

8. “Multiple endocrine neoplasia 2” pubblicato nel volume Update in Neuroendocrinology,

Editors: Baldelli, Casanueva, Tamburrano, Pubblicazioni Medico Scientifiche Publisher 2004

9. “Meccanismo di secrezione, dell’azione ormonale e della risposta tissutale” pubblicato

nel volume Endocrinologia, 1992 Editors: Pinchera, Fenzi, UTET Publisher

10. “ Molecular Markers in Thyroid Fine-Needle Aspiration Biopsies” pubblicato nel volume

“Minimally Invasive Therapies for Endocrine Neck Diseases”, Editors: Lombardi CP,

Bellantone R. Springer 2016, 37-51


Altre capacità e competenze

PROCEEDING MEETINGS OF REPORTS:

1. Arturi F, Chiefari E, Scarpelli D, Russo D, Filetti S “Strumenti di diagnosi molecolare in endocrinologia” pubblicato nel volume Aspetti di diagnosi molecolare e

terapia genica delle neoplasie endocrine, (Atti del convegno – Padova, 29 ottobre 1999) Editors: Barzon,

Bonaguro, Boscaro, Palù 2000 -Time Science Publisher

2. Russo D, Arturi F, Ferretti E, Filetti S “Iodine transport in normal and neoplastic thyroid cells” pubblicato nel volume “Signal transduction and

neoplastic transformation in endocrine systems: molecular mechanisms and clinical aspects” (Atti del

Convegno presso l’Accademia Nazionale dei Lincei 5-6/04/2002), Bardi Editore Publisher

3. Irace C, Maranghi M, Filetti S “Ipotiroidismo, lipidi e rischio cardiovascolare” pubblicato nel volume Ipotiroidismi: dalla fisiopatologia al

trattamento, (Atti del convegno – Vicenza, 27 maggio 2005) Editors: Basso A., Giochetti M.

- 2006

R 4. Durante C, Romagnoli E, Maranghi M, D’Aloiso L, Minisola S, D’Erasmo E, Filetti S Hyperparathyroidism in multiple endocrine neoplasia type IIA

Clinical Cases in Mineral and Bone Metabolism 2006, 3(2): 162 – 166

5. Filetti S, Durante C, Maranghi M A genetic based disease management in inherited cancer syndromes: the multiple endrocrine neoplasia

model.

Supportive & Palliative Cancer Care, Suppl. 2006, 2: 13-16

PEER-REVIEWED ARTICLES

ARTICLES N° = 284

H INDEX = 59 (ISI WEB OF SCIENCE) Times cited : 12.871

1. Filetti S. Quo vadis Endocrine-Part II.Endocrine. 2019 Jan;63(1):1-2. doi: 10.1007/s12020-018-1828-5. No abstract available. PMID:30591986;

2. Raparelli V, Proietti M, Lenzi A, Basili S; EVA Collaborators. Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design.J Cardiovasc Transl Res. 2018 Dec 3. doi: 10.1007/s12265-018-9846-5. [Epub ahead of print] PMID:30511337;

3. Pecce V, Sponziello M, Damante G, Rosignolo F, Durante C, Lamartina L, Grani G, Russo D, di Gioia CR, Filetti S, Verrienti A. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency. PLoS Genet. 2018 Oct 15;14(10):e1007678. doi: 10.1371/journal.pgen.1007678. eCollection 2018 Oct. PMID:30321177;

4. Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS.J Clin Endocrinol Metab. 2019 Jan 1;104(1):95-102. doi: 10.1210/jc.2018-01674. PMID:30299457;

https://www.ncbi.nlm.nih.gov/pubmed/30591986https://www.ncbi.nlm.nih.gov/pubmed/30511337https://www.ncbi.nlm.nih.gov/pubmed/30511337https://www.ncbi.nlm.nih.gov/pubmed/30321177https://www.ncbi.nlm.nih.gov/pubmed/30321177https://www.ncbi.nlm.nih.gov/pubmed/30299457https://www.ncbi.nlm.nih.gov/pubmed/30299457


5. Grani G, Lamartina L, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Sonographically Estimated Risks of Malignancy for Thyroid Nodules Computed with Five Standard Classification Systems: Changes over Time and Their Relation to Malignancy. Thyroid. 2018 Sep;28(9):1190-1197. doi: 10.1089/thy.2018.0178. PMID:30105949

6. Lamartina L, Grani G, Durante C, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. Nat Rev Endocrinol. 2018 Sep;14(9):538-551. doi: 10.1038/s41574-018-0068-3. Review. PMID:30069030

7. Sponziello M, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, Durante C, Filetti S, Fadda G. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma. Endocrine. 2018 Apr 26. doi: 10.1007/s12020-018-1611-7.

8. Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D; Italian Study Group on the Diffusion of CSII. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):335-342. doi: 10.1016/j.numecd.2017.12.001. PMID:29428572.

9. Lamartina L, Grani G, Durante C, Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res. 2018 Jan 18;7:86. doi: 10.12688/f1000research.12811.1. eCollection 2018. Review.PMID:29399330.

10. Allegri L, Mio C, Russo D, Filetti S, Baldan F. Effects of HuR downregulation on anaplastic thyroid cancer cells. Oncol Lett. 2018 Jan;15(1):575-579. doi: 10.3892/ol.2017.7289. Epub 2017 Oct 30.PMID:29285201.

11. Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, Durante C, Filetti S, Verrienti A Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. J Endocr Soc. 2017 Jan 12;1(1):3-13. doi: 10.1210/js.2016-1032. eCollection 2017 Jan 1.PMID:29264441

12. Mio C, Conzatti K, Baldan F, Allegri L, Sponziello M, Rosignolo F, Russo D, Filetti S, Damante G. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.Oncol Rep. 2018 Feb;39(2):582-588. doi: 10.3892/or.2017.6152. Epub 2017 Dec 12. PMID:29251329

13. Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzì AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, Durante C, Verrienti A. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.Hum Mutat. 2017 Dec 8. doi: 10.1002/humu.23378. [Epub ahead of print] PMID:29219214

14. Allegri L, Rosignolo F, Mio C, Filetti S, Baldan F, Damante G. Effects of nutraceuticals on anaplastic thyroid cancer cells. J Cancer Res Clin Oncol. 2017 Dec 2. doi: 10.1007/s00432-017-2555-7. [Epub ahead of print] PMID:29197967

15. Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, Durante C. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. Endocr Relat Cancer. 2017 Nov 30. pii: ERC-17-0453. doi: 10.1530/ERC-17-0453. [Epub ahead of print] PMID:29192093

16. Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine. 2017 Nov 6. doi: 10.1007/s12020-017-1455-6. [Epub ahead of print] PMID:29110129

17. Grani G, Lamartina L, Durante C, Filetti S, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol. 2017 Oct 25. pii: S2213-8587(17)30325-X. doi: 10.1016/S2213-8587(17)30325-X. [Epub ahead of print] Review. PMID:29102432

18. Lamartina L, Durante C, Lucisano G, Grani G, Bellantone RA, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone PP, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Mian C, Spiazzi G, Persani L, Barbaro D, Nicolucci A, Filetti S. Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory (ITCO#1).Thyroid. 2017 Oct 12. doi: 10.1089/thy.2017.0299. PMID:29020892.

19. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes.N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. PMID:28854085.

20. Grani G, Bruno R, Lucisano G, Costante G, Meringolo D, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Cooper DS, Filetti S, Durante C. Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume. Thyroid. 2017 Sep 14. doi: 10.1089/thy.2017.0201. PMID:28806880.

21. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. PMID:8605603.

22. Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, Durante C, Grani G, Lamartina L, Forte S, Martinetti D, Giuffrida D, Russo D, Basolo F, Filetti S, Sponziello M. MicroRNA-based molecular classification of papillary thyroid carcinoma. Int J Oncol. 2017 May;50(5):1767-1777. doi: 10.3892/ijo.2017.3960. Epub 2017 Apr 7. PMID:28393181.

23. Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, Filetti S, Damante G, Russo D, Bulotta S. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol Cell Endocrinol. 2017 Mar 10. pii: S0303-7207(17)30176-4. doi: 10.1016/j.mce.2017.03.007 PMID:28288903.

24. Giannetta E, Isidori AM, Durante C, Di Gioia C, Longo F, Tombolini V, Bulzonetti N, Graziadio C, Pofi R, Gianfrilli D, Verrienti A, Carletti R, Filetti S, Lenzi A, Baroli A. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. Medicine (Baltimore). 2017 Feb;96(6):e5621. doi: 10.1097/MD.0000000000005621.PMID:28178124

25. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C. Papillary thyroid carcinomas with biochemical

https://www.ncbi.nlm.nih.gov/pubmed/30105949https://www.ncbi.nlm.nih.gov/pubmed/30105949https://www.ncbi.nlm.nih.gov/pubmed/30069030https://www.ncbi.nlm.nih.gov/pubmed/30069030https://www.ncbi.nlm.nih.gov/pubmed/29700698https://www.ncbi.nlm.nih.gov/pubmed/29700698https://www.ncbi.nlm.nih.gov/pubmed/29428572https://www.ncbi.nlm.nih.gov/pubmed/29428572https://www.ncbi.nlm.nih.gov/pubmed/29399330https://www.ncbi.nlm.nih.gov/pubmed/29285201https://www.ncbi.nlm.nih.gov/pubmed/29285201https://www.ncbi.nlm.nih.gov/pubmed/29264441https://www.ncbi.nlm.nih.gov/pubmed/29264441https://www.ncbi.nlm.nih.gov/pubmed/29251329https://www.ncbi.nlm.nih.gov/pubmed/29251329https://www.ncbi.nlm.nih.gov/pubmed/29219214https://www.ncbi.nlm.nih.gov/pubmed/29219214https://www.ncbi.nlm.nih.gov/pubmed/29219214https://www.ncbi.nlm.nih.gov/pubmed/29197967https://www.ncbi.nlm.nih.gov/pubmed/29197967https://www.ncbi.nlm.nih.gov/pubmed/29192093https://www.ncbi.nlm.nih.gov/pubmed/29110129https://www.ncbi.nlm.nih.gov/pubmed/29110129https://www.ncbi.nlm.nih.gov/pubmed/29102432https://www.ncbi.nlm.nih.gov/pubmed/29102432https://www.ncbi.nlm.nih.gov/pubmed/29020892https://www.ncbi.nlm.nih.gov/pubmed/29020892https://www.ncbi.nlm.nih.gov/pubmed/28854085https://www.ncbi.nlm.nih.gov/pubmed/28806880https://www.ncbi.nlm.nih.gov/pubmed/28806880https://www.ncbi.nlm.nih.gov/pubmed/28605603https://www.ncbi.nlm.nih.gov/pubmed/28605603https://www.ncbi.nlm.nih.gov/pubmed/28393181https://www.ncbi.nlm.nih.gov/pubmed/28393181https://www.ncbi.nlm.nih.gov/pubmed/28288903https://www.ncbi.nlm.nih.gov/pubmed/28288903https://www.ncbi.nlm.nih.gov/pubmed/28178124https://www.ncbi.nlm.nih.gov/pubmed/28178124https://www.ncbi.nlm.nih.gov/pubmed/26668060


incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine. 2016 Nov;54(2):467-475. PMID: 26668060.

26. Grani G, Lamartina L, Ascoli V, Bosco D, Nardi F, D'Ambrosio F, Rubini A, Giacomelli L, Biffoni M, Filetti S, Durante C, Cantisani V. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules. Endocrine. 2016 Oct 31. [Epub ahead of print] PMID:27804016.

27. Essig GF Jr, Porter K, Schneider D, Arpaia D, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas LH, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study. Thyroid. 2016 Nov;26(11):1563-1572. PMID:27604949.

28. Cohen O, Filetti S, Castañeda J, Maranghi M, Glandt M. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.Diabetes Care. 2016 Aug;39 Suppl 2:S180-6. doi: 10.2337/dcS15-3029.

29. Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, De Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C. RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocr Relat Cancer. 2016 Jul 8. pii: ERC-16-0132. [Epub ahead of print].

30. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

31. Lamartina L, Deandreis D, Durante C, Filetti S. ENDOCRINE TUMOURS: Imaging in the follow up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol. 2016 Jun 1. pii: EJE-16-0088.

32. Rosignolo F, Sponziello M, Durante C, Puppin C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G. Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma. PLoS One. 2016 Jun 1;11(6):e0156658. doi: 10.1371/journal.pone.0156658. eCollection 2016.

33. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab. 2016 May 17:jc20161440.

34. Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti S, Damante G, Russo D, Bulotta S. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol Cell Endocrinol. 2016 Aug 15;431:123-32. doi: 10.1016/j.mce.2016.05.007. Epub 2016 May 10.

35. Filetti S, Ladenson PW, Biffoni M, D'Ambrosio MG, Giacomelli L, Lopatriello S. The true cost of thyroid surgery determined by a micro-costing approach. Endocrine. 2016 May 12.

36. Conget I, Castaneda J, Petrovski G, Guerci B, Racault AS, Reznik Y, Cohen O, Runzis S, de Portu S, Aronson R; OpT2mise Study Group. The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study. Diabetes Technol Ther. 2016 Jan;18(1):22-8. doi: 10.1089/dia.2015.0159. Epub 2015 Aug 4.

37. Rosato L, De Crea C, Bellantone R, Brandi ML, De Toma G, Filetti S, Miccoli P, Pacini F, Pelizzo MR, Pontecorvi A, Avenia N, De Pasquale L, Chiofalo MG, Gurrado A, Innaro N, La Valle G, Lombardi CP, Marini PL, Mondini G, Mullineris B, Pezzullo L, Raffaelli M, Testini M, De Palma M. Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB). J Endocrinol Invest. 2016 Apr 8. [Epub ahead of print]. PMID: 27059212.

38. Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppin C, Filetti S, Durante C, Russo D, Orlacchio A, Di Cristofano A, Di Loreto C, Damante G. MCM5 as a target of BET inhibitors in thyroid cancer cells.Endocr Relat Cancer. 2016 Feb 24. pii: ERC-15-0322.

39. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine. 2015 Dec 14. [Epub ahead of print] PMID:26668060.

40. Sponziello M, Durante C, Filetti S. HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med. 2015 Nov 19;373(21):2085-6. doi: 10.1056/NEJMc1511631#SA3. No abstract available. PMID: 26581004.

41. Tallini G, de Biase D, Durante C, Acquaviva G, Bisceglia M, Bruno R, Bacchi Reggiani ML, Casadei GP, Costante G, Cremonini N, Lamartina L, Meringolo D, Nardi F, Pession A, Rhoden KJ, Ronga G, Torlontano M, Verrienti A, Visani M, Filetti S. BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod Pathol. 2015 Oct;28(10):1343-59. doi: 10.1038/modpathol.2015.92.

42. Passon N, Bregant E, Sponziello M, Dima M, Rosignolo F, Durante C, Celano M, Russo D, Filetti S, Damante G. Somatic amplifications and deletions in genome of papillary thyroid carcinomas. Endocrine. 2015 Nov;50(2):453-64. doi 10.1007/s12020-015-0592, PMID: 25863487.

43. De Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei GP, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A. Tert promoter mutations in thyroid papillary microcarcinomas. Thyroid. 2015 Sep; 25(9): 1013-9. doi: 10.1089/thy.2015.0101. PMID: 26148423.

44. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S.The natural history of benign thyroid nodules. JAMA. 2015 Mar 3;313(9):926-35. doi: 10.1001/jama.2015.0956.

45. Baldan F, Mio C, Allegri L, Puppin C, Russo D, Filetti S, Damante G. Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line. Int J Endocrinol. 2015;2015:978371. doi: 10.1155/2015/978371.

46. Lamartina L, Durante C, Filetti S, Cooper DS. Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A systematic review of the literature.J Clin Endocrinol Metab. 2015 May;100(5):1748-61. Doi: 10.1210jc2014-3882. PMID: 25679996.

47. Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, Filetti S. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.Expert Opin Drug Metab Toxicol. 2015 Jan;11(1):125-37 doi: 10.1517/17425255.2015.986457. PMID: 25418019.

48. Reznik Y, Huang S; OpT2mise Study Group. Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations.Diabetes Technol Ther. 2014 Nov;16(11):816-8, doi: 10.1089/dia.2014.0261. PMID: 25192407.

https://www.ncbi.nlm.nih.gov/pubmed/27804016https://www.ncbi.nlm.nih.gov/pubmed/27804016https://www.ncbi.nlm.nih.gov/pubmed/27604949https://www.ncbi.nlm.nih.gov/pubmed/27604949http://www.ncbi.nlm.nih.gov/pubmed/27440831http://www.ncbi.nlm.nih.gov/pubmed/27440831http://www.ncbi.nlm.nih.gov/pubmed/27402614http://www.ncbi.nlm.nih.gov/pubmed/27402614http://www.ncbi.nlm.nih.gov/pubmed/27295427http://www.ncbi.nlm.nih.gov/pubmed/27252484http://www.ncbi.nlm.nih.gov/pubmed/27252484http://www.ncbi.nlm.nih.gov/pubmed/27249794http://www.ncbi.nlm.nih.gov/pubmed/27186860http://www.ncbi.nlm.nih.gov/pubmed/27186860http://www.ncbi.nlm.nih.gov/pubmed/27173027http://www.ncbi.nlm.nih.gov/pubmed/27173027http://www.ncbi.nlm.nih.gov/pubmed/27172916http://www.ncbi.nlm.nih.gov/pubmed/27172916http://www.ncbi.nlm.nih.gov/pubmed/26241790http://www.ncbi.nlm.nih.gov/pubmed/26241790http://www.ncbi.nlm.nih.gov/pubmed/27059212http://www.ncbi.nlm.nih.gov/pubmed/27059212http://www.ncbi.nlm.nih.gov/pubmed/27059212http://www.ncbi.nlm.nih.gov/pubmed/26911376http://www.ncbi.nlm.nih.gov/pubmed/26668060http://www.ncbi.nlm.nih.gov/pubmed/26668060http://www.ncbi.nlm.nih.gov/pubmed/26668060http://www.ncbi.nlm.nih.gov/pubmed/26581004http://www.ncbi.nlm.nih.gov/pubmed/26271724http://www.ncbi.nlm.nih.gov/pubmed/26271724http://www.ncbi.nlm.nih.gov/pubmed/25863487http://www.ncbi.nlm.nih.gov/pubmed/25734734http://www.ncbi.nlm.nih.gov/pubmed/25705225http://www.ncbi.nlm.nih.gov/pubmed/25705225http://www.ncbi.nlm.nih.gov/pubmed/25679996http://www.ncbi.nlm.nih.gov/pubmed/25679996http://www.ncbi.nlm.nih.gov/pubmed/25418019http://www.ncbi.nlm.nih.gov/pubmed/25418019http://www.ncbi.nlm.nih.gov/pubmed/25192407http://www.ncbi.nlm.nih.gov/pubmed/25192407


49. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.Lancet. 2014 Oct 4;384(9950):1265-72. doi: 10.1016/S0140-6736(14)61037-0. PMID:24998009.

50. Micali S, Bulotta S, Puppin C, Territo A, Navarra M, Bianchi G, Damante G, Filetti S, Russo D. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.BMC Cancer. 2014 Apr 30;14:303. doi: 10.1186/1471-2407-14-303.

51. Baldan F, Lavarone E, Di Loreto C, Filetti S, Russo D, Damante G, Puppin C Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene. Mol Biol Rep. 2014 Aug;41(8):5257-65. doi: 10.1007/s11033-014-3397-x.

52. Paolino D, Cosco D, Gaspari M, Celano M, Wolfram J, Voce P, Puxeddu E, Filetti S, Celia C, Ferrari M, Russo D, Fresta M.Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials. 2014 Aug;35(25):7101-9. doi: 10.1016/j.biomaterials.2014.04.088.

53. Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S.Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell Endocrinol. 2014 Jul 5;392(1-2):8-13. doi: 10.1016/j.mce.2014.04.016.

54. Aronson R, Cohen O, Conget I, Runzis S, Castaneda J, de Portu S, Lee S, Reznik Y; OpT2mise Study Group. OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes-research design and methods.Diabetes Technol Ther. 2014 Jul;16(7):414-20. doi: 10.1089/dia.2013.0363.

55. Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Toteda M, Redler A, Ronga G, Filetti S, Monzani F. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.Thyroid. 2014 Jul;24(7):1139-45, doi: 10.1089/thy.2013.0698.

56. Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine. 2014 Nov;47(2):528-36. doi: 10.1007/s12020-014-0204-3.

57. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E.Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. J Clin Endocrinol Metab. 2014 May;99(5):E832-40, doi: 10.1210/jc.2013-3351.

58. Puxeddu E, Filetti S BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? Endocrine. 2014 Apr;45(3):341-3, doi: 10.1007/s12020-013-0139-0 .

59. D'Agostino M, Sponziello M, Puppin C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol. 2014 Jan 30;52(2):121-31, doi: 10.1530/JME-13-0160.

60. Maggisano V, Puppin C, Celano M, D’Agostino M, Sponziello M, Micali S, Navarra M, Damante G, Filetti S. & Russo D. Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells. Endocrine. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4.

61. Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, Schlumberger M, Tolstrup LK, Zamorano JL, Capdevila J. Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies. Adv Ther. 2013 Nov;30(11):945-66. doi: 10.1007/s12325-013-0069-5.

62. Essig GF, Porter K, Schneider D, Debora A, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas L, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Fine Needle Aspiration and Medullary Thyroid Carcinoma: The Risk of Inadequate Preoperative Evaluation and Initial Surgery when Relying Upon FNAB Cytology Alone. Endocr Pract. 2013 Nov-Dec;19(6):920-7. doi: 10.4158/EP13143.OR.

63. Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology. 2013 Sep;154(9):3043-53, doi: 10.1210/en.2013-1028.

64. Bulotta S, Corradino R, Celano M, Maiuolo J, D'Agostino M, Oliverio M, Procopio A, Filetti S, Russo D. Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells. J Mol Endocrinol. 2013 Jun 29;51(1):181-9. doi: 10.1530/JME-12-0241.

65. Aghini-Lombardi F, Vitti P, Antonangeli L, Fiore E, Piaggi P, Pallara A, Consiglio E, Pinchera A; Southern Italy Study Group for Iodine Deficiency Disorders. The size of the community rather than its geographical location better defines the risk of iodine deficiency: results of an extensive survey in Southern Italy. J Endocrinol Invest. 2013 May;36(5):282-6.

66. Durante C, Paciaroni A, Plasmati K, Trulli F, Filetti S Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine. 2013 Oct;44(2):334-42. doi: 10.1007/s12020-013-9943-9.

67. Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for the post-operative management. Endocr Relat Cancer. 2013 Jun 24;20(4):R141-54. doi: 10.1530/ERC-13-0066.

68. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S; Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance. J Clin Endocrinol Metab. 2013 Feb;98(2):636-42. doi: 10.1210/jc.2012-3401.

69. Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, Damante G. Targeting histone deacetylase in thyroid cancer. Expert Opin Ther Targets. 2013 Feb;17(2):179-93. doi: 10.1517/14728222.2013.740013.

70. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799.

71. Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, Sponziello M, Migaldi M, Navarra M, Bianchi G, Filetti S, Russo D. Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. J Endocrinol. 2013 Jan 18;216(2):125-33. doi: 10.1530/JOE-12-0495.

http://www.ncbi.nlm.nih.gov/pubmed/24998009http://www.ncbi.nlm.nih.gov/pubmed/24998009http://www.ncbi.nlm.nih.gov/pubmed/24998009http://www.ncbi.nlm.nih.gov/pubmed/24884806http://www.ncbi.nlm.nih.gov/pubmed/24884806http://www.ncbi.nlm.nih.gov/pubmed/24844212http://www.ncbi.nlm.nih.gov/pubmed/24844212http://www.ncbi.nlm.nih.gov/pubmed/24836306http://www.ncbi.nlm.nih.gov/pubmed/24813658http://www.ncbi.nlm.nih.gov/pubmed/24813658http://www.ncbi.nlm.nih.gov/pubmed/24813658http://www.ncbi.nlm.nih.gov/pubmed/24735134http://www.ncbi.nlm.nih.gov/pubmed/24735134http://www.ncbi.nlm.nih.gov/pubmed/24702238http://www.ncbi.nlm.nih.gov/pubmed/24702238http://www.ncbi.nlm.nih.gov/pubmed/24702238http://www.ncbi.nlm.nih.gov/pubmed/24569963http://www.ncbi.nlm.nih.gov/pubmed/24569963http://www.ncbi.nlm.nih.gov/pubmed/24517146http://www.ncbi.nlm.nih.gov/pubmed/24517146http://www.ncbi.nlm.nih.gov/pubmed/24366644http://www.ncbi.nlm.nih.gov/pubmed/24366644http://www.ncbi.nlm.nih.gov/pubmed/24353283http://www.ncbi.nlm.nih.gov/pubmed/24353283http://www.ncbi.nlm.nih.gov/pubmed/24249433http://www.ncbi.nlm.nih.gov/pubmed/24249433http://www.ncbi.nlm.nih.gov/pubmed/23757627http://www.ncbi.nlm.nih.gov/pubmed/23757627http://www.ncbi.nlm.nih.gov/pubmed/23751876http://www.ncbi.nlm.nih.gov/pubmed/23751876http://www.ncbi.nlm.nih.gov/pubmed/23718964http://www.ncbi.nlm.nih.gov/pubmed/23712195http://www.ncbi.nlm.nih.gov/pubmed/23712195http://www.ncbi.nlm.nih.gov/pubmed/23293334http://www.ncbi.nlm.nih.gov/pubmed/23293334http://www.ncbi.nlm.nih.gov/pubmed/23234477http://www.ncbi.nlm.nih.gov/pubmed/23234477http://www.ncbi.nlm.nih.gov/pubmed/23121378http://www.ncbi.nlm.nih.gov/pubmed/23121378http://www.ncbi.nlm.nih.gov/pubmed/23117572http://www.ncbi.nlm.nih.gov/pubmed/23117572


72. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003.

73. D'Elia AV, Grimaldi F, Pizzolitto S, De Maglio G, Bregant E, Passon N, Franzoni A, Verrienti A, Tamburrano G, Durante C,Filetti S, Fogolari F, Russo D, Damante G. A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma. Clin Endocrinol (Oxf). 2012 Sep 5. doi: 10.1111/cen.12032.

74. Lavarone E, Puppin C, Passon N, Filetti S, Russo D, Damante G. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines. Mol Cell Endocrinol. 2012 Sep 5. pii: S0303-7207(12)00414-5. doi: 10.1016/j.mce.2012.08.019.

75. Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M; for the 1860-LIRA-DPP-4 Study Group. Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial. Diabetes Care. 2012 Oct;35(10):1986-93.]

76. Celano M, Sponziello M, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, Durante C, Sacco R, Filetti S, Russo D. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. Endocrine. 2013 Feb;43(1):147-53. doi: 10.1007/s12020-012-9747-3.

77. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S. Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? J Clin Endocrinol Metab. 2012 Aug;97(8):2748-2753.

78. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

79. Passon N, Puppin C, Lavarone E, Bregant E, Franzoni A, Hershman JM, Fenton MS, D'Agostino M, Durante C, Russo D, Filetti S, Damante G. Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells. Thyroid. 2012 May;22(5):487-93. doi: 10.1089/thy.2011.0360.

80. Maranghi M, Prudente S, D'Erasmo L, Morini E, Ciociola E, Coletta P, Verrienti A, Arciello S, Copetti M, Pellegrini F, Santini SA, Morano S, Filetti S, Trischitta V. The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals. Nutr Metab Cardiovasc Dis. 2013 Jun;23(6):505-10. doi: 10.1016/j.numecd.2011.11.003.]

81. Passon N, Puppin C, Lavarone E, Bregant E, Franzoni A, Hershman J, Fenton M, D'Agostino M, Durante C, Russo D, Filetti S, Damante G. CREM inhibits promoter activity of NIS gene in thyroid cancer cells.Thyroid. 2012 Feb 28.

82. D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggisano V, Verrienti A, Durante C, Filetti S, Puxeddu E, Russo D. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid. 2012 Feb;22(2):138-44. doi: 10.1089/thy.2011.0060.

83. Russo D, Costante G, Bruno R, Sponziello M, Tamburrano G, Dima M, Sacco R, Giacomelli L, Durante C, Filetti S. TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. Endocrine. 2011 Dec;40(3):492-4. doi: 10.1007/s12020-011-9525-7.

84. Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C.Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. Oncol Rep. 2011 Nov;26(5):1075-80. doi: 10.3892/or.2011.1422.

85. Durante C, Filetti S. Management of Papillary Thyroid Cancer Patients in Absence of Postoperative Radioiodine Remnant Ablation: tailoring Follow-Up by Neck Sonography. J Clin Endocrinol Metab. 2011 Oct;96(10):3059-61. doi: 10.1210/jc.2011-1379.

86. Mastroianno S, Torlontano M, Scillitani A, D'Aloiso L, Verrienti A, Bonfitto N, De Bonis A, D'Agruma L, Muscarella LA, Guarnieri V, Dicembrino F, Maranghi M, Durante C, Filetti S. Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. Endocrine. 2011 Dec;40(3):481-5. doi: 10.1007/s12020-011-9501-2.

87. Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur J Endocrinol. 2011 Sep;165(3):455-63. doi: 10.1530/EJE-11-0283.

88. Russo D, Scipioni A, Durante C, Ferretti E, Gandini L, Maggisano V, Paoli D, Verrienti A, Costante G, Lenzi A, Filetti S. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. Endocrine. 2011 Aug;40(1):35-40. doi: 10.1007/s12020-011-9469-y.

89. Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, Filetti S, Russo D, Damante G Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun. 2010 Jul 2;397(3):499-504. doi: 10.1016/j.bbrc.2010.05.142.

90. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M; for the 1860-LIRA-DPP-4 Study Group.One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011 Mar 1. doi: 10.1111/j.1742-1241.2011.02656.x.

91. Russo D, Damante G, Puxeddu E, Durante C, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets, J Mol Endocrinol. 2011 Apr 28;46(3):R73-81. doi: 10.1530/JME-10-0150.

92. Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163.

93. Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. Acta Diabetol. 2012 Jun;49(3):193-7. doi: 10.1007/s00592-

http://www.ncbi.nlm.nih.gov/pubmed/23063367http://www.ncbi.nlm.nih.gov/pubmed/23063367http://www.ncbi.nlm.nih.gov/pubmed/23063367http://www.ncbi.nlm.nih.gov/pubmed?term=D'Elia%20AV%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Grimaldi%20F%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Pizzolitto%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=De%20Maglio%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Bregant%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Passon%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Franzoni%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Verrienti%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Tamburrano%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Tamburrano%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Durante%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Filetti%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Fogolari%20F%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Russo%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Damante%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22946750http://www.ncbi.nlm.nih.gov/pubmed/22946750http://www.ncbi.nlm.nih.gov/pubmed?term=Lavarone%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22982218http://www.ncbi.nlm.nih.gov/pubmed?term=Puppin%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22982218http://www.ncbi.nlm.nih.gov/pubmed?term=Passon%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22982218http://www.ncbi.nlm.nih.gov/pubmed?term=Filetti%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22982218http://www.ncbi.nlm.nih.gov/pubmed?term=Russo%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22982218http://www.ncbi.nlm.nih.gov/pubmed?term=Damante%20G%5BAuthor%5D&cauthor=true&cauthor_uid=22982218http://www.ncbi.nlm.nih.gov/pubmed/22982218http://www.ncbi.nlm.nih.gov/pubmed/21850379http://www.ncbi.nlm.nih.gov/pubmed/21850379http://www.ncbi.nlm.nih.gov/pubmed/21678021http://www.ncbi.nlm.nih.gov/pubmed/21678021http://www.ncbi.nlm.nih.gov/pubmed/20515654


011-0261-5. 94. Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening

appropriate in patients with nodular thyroid disease? Oncologist. 2011;16(1):49-52. doi: 10.1634/theoncologist.2010-0344.

95. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S, Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab. 2010 Nov;95(11):4882-8. doi: 10.1210/jc.2010-0762

96. Zinnamosca L, Petramala L, Cotesta D, Marinelli C, Sciomer S, Cavallaro G, Ciardi A, Massa R, De Toma G, Filetti S, Letizia C. Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report. Endocrine. 2010 Dec;38(3):313-9. doi: 10.1007/s12020-010-9394-5.

97. Sponziello ML, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression.. Horm Metab Res. 2011 Jan;43(1):22-5. doi: 10.1055/s-0030-1265226.

98. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010 Apr 24;375(9724):1447-56, doi: 10.1016/S0140-6736(10)60307-8.

99. Paolino D, Cosco D, Racanicchi L, Trapasso E, Celia C, Iannone M, Puxeddu E, Costante G, Filetti S, Russo D, Fresta M.Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release. 2010 Jun 1;144(2):144-50, doi: 10.1016/j.jconrel.2010.02.021.

100. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B, Filetti S, Lenti L, Morano S. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb. 2010 Jun 30;17(6):539-45.

101. Castellone MD, Verrienti A, Rao DM, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: Functional characterization. Clin Endocrinol (Oxf). 2010 Oct;73(4):529-34. doi: 10.1111/j.1365-2265.2009.03757.

102. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, De Gaetani C, Filetti S, Bianchi G, Russo D.Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology. 2010 Apr;75(4):773-8. doi: 10.1016/j.urology.2009.10.011.

103. Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark OH. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery. 2009 Dec;146(6):1073-80. doi: 10.1016/j.surg.2009.09.012.

104. Cotesta D, Petramala L, Serra V, Pergolini M, Crescenzi E, Zinnamosca L, De Toma G, Ciardi A, Carbone I, Massa R, Filetti S, Letizia C. Clinical experience with pheochromocytoma in a single centre over 16 years. High Blood Press Cardiovasc Prev. 2009 Dec;16(4):183-93. doi: 10.2165/11530430.

105. Puxeddu E, Filetti S. The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus- to evidence-based practice. Thyroid. 2009;19(11):1145-7. doi: 10.1089/thy.2009.1601.

106. Maranghi M, Pugliese F, Cianci R, Colotto M, Durante C, Anatra MG, Coletta P, Mercuri S, Rossetti M, Morano S, Filetti S. Atherosclerosis renal artery stenosis and in stent restenosis in diabetic patient: targeting on Diabetic Dyslipidemia is a key intervention. J Endocrinol Invest. 2009 Oct 15, doi: 10.3275/6567.

107. Sponziello M, Scipioni A, Durante C, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D Regulation of Sodium/Iodide Symporter and Lactoperoxidase Expression in four Human Breast Cancer Cell Lines. J Endocrinol Invest. 2009 Sep 30. doi: 10.3275/6522.

108. Corleto VD, Cotesta D, Petramala L, Panzuto F, Pagnini C, Masoni L, Verrienti A, Delle Fave G, Filetti S, Letizia C. Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease. JOP. 2009;10(5):562-5.

109. Marques LH, Ferraz-Filho JR, Lins-Filho ML, Maciel MG, Yoshitake R, Filetti S. Interictal SPECT in the presurgical evaluation in epileptic patients with normal MRI or bilateral mesial temporal sclerosis. Arq Neuropsiquiatr. 2009 Sep;67(3A):639-42.

110. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, Trischitta V, Filetti S. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2009;32(8):1550-2. doi: 10.2337/dc09-0256.

111. Costante G, Filetti S. Diagnosis: Thyroglobulin in fine-needle aspirates-a clue to metastasis? Nat Rev Endocrinol. 2009; 5(5):249-50. doi: 10.1038/nrendo.2009.55.

112. Gatti A, Baroni MG, Romeo S, Mandosi E, Fallarino M, Bezzi M, Paciucci L, Filetti S, Morano S. A case of severe occult ectopic adrenocorticotropin syndrome treated with retrograde venous adrenal ablation using ethanol. J Endocrinol Invest. 2008 Dec;31(12):1135-6.

113. Bruno R, Giannasio P, Chiarella R, Capula C, Russo D, Filetti S, Costante G. Identification of a neck lump as a lymph node metastasis from an occult controlateral papillary microcarcinoma of the thyroid: key role of thyroglobulin assay in the fine-needle aspirate.Thyroid. 2009;19(5):531-3. doi: 10.1089/thy.2009.0049.

114. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacchè M, Mori L, Pignataro V, Bernini G, Giachè V, Bacca A, Biondi B, Corona G, Di Trapani G, Grossrubatscher E, Reimondo G, Arnaldi G, Giacchetti G, Veglio F, Loli P, Colao A, Ambrosio MR, Terzolo M, Letizia C, Ercolino T, Opocher G; Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94(5):1541-7. doi: 10.1210/jc.2008-2419.

115. Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid. 2009;19(3):247-55. doi: 10.1089/thy.2008.0235

116. Venditti M, Falcone M, Corrao S, Licata G, Serra P; Study Group of the Italian Society of Internal Medicine Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia.Ann Intern Med. 2009 Jan 6;150(1):19-26.

117. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab. 2009;5(1):35-44 doi: 10.1038/ncpendmet1023.

http://www.ncbi.nlm.nih.gov/pubmed/20660054http://www.ncbi.nlm.nih.gov/pubmed/20660054http://www.ncbi.nlm.nih.gov/pubmed/20886414http://www.ncbi.nlm.nih.gov/pubmed/20886414http://www.ncbi.nlm.nih.gov/pubmed/20184929http://www.ncbi.nlm.nih.gov/pubmed/20184929http://www.ncbi.nlm.nih.gov/pubmed/20134099http://www.ncbi.nlm.nih.gov/pubmed/20134099http://www.ncbi.nlm.nih.gov/pubmed/19969326http://www.ncbi.nlm.nih.gov/pubmed/19958934http://www.ncbi.nlm.nih.gov/pubmed/19958934http://www.ncbi.nlm.nih.gov/pubmed/23334910http://www.ncbi.nlm.nih.gov/pubmed/19416000?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19416000?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19416000?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19223516?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19223516?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19207009?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19207009?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19079272?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSumhttp://www.ncbi.nlm.nih.gov/pubmed/19079272?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


118. Petramala L, Cotesta D, Filetti S, Letizia C.Pigmented 'black' cardiac paraganglioma in a patient with a novel germ-line mutation.Eur J Cardiothorac Surg.; 35:189 doi: 10.1016/j.ejcts.2008.10.00.7.

119. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid. 2008;18(10):1049-53. doi: 10.1089/thy.2008.0160.

120. Capezzone M, Cantara S, Marchisotta S, Filetti S, De Santi MM, Rossi B, Ronga G, Durante C, Pacini F.Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab. 2008;93(10):3950-7. doi: 10.1210/jc.2008-0372.

121. Ferretti E, Tosi E, Po A, Scipioni A, Morisi R, Espinola MS, Russo D, Durante C, Schlumberger M, Screpanti I, Filetti S, Gulino A. Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J Clin Endocrinol Metab. 2008;93(10):4080-7. doi: 10.1210/jc.2008-0528.

122. Durante C, Cava F, Paciaroni A, Filetti S. Benign thyroid nodules: diagnostic and therapeutic approach. Recenti Prog Med. 2008;99(5):263-70.

123. Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer. 2008;15(2):499-510. doi: 10.1677/ERC-07-0243

124. Petramala L, Cavallaro G, Polistena A, Cotesta D, Verrienti A, Ciardi A, Lucia P, Filetti S, D'Erasmo E, De Toma G, Letizia C.Multiple catecholamine-secreting paragangliomas: diagnosis after hemorrhagic stroke in a young woman. Endocr Pract. 2008;14(3):340-6.

125. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-28. doi: 10.1159/000127442.

126. Puppin C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G. High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. J Endocrinol. 2008;197(2):401-8. doi: 10.1677/JOE-07-0618.

127. Xu J, Filetti S, Hershman JM. Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors. Thyroid. 2008;18(5):533-9. doi: 10.1089/thy.2007.0312

128. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab. 2008;19(4):138-45. doi: 10.1016/j.tem.2007.12.003.

129. Vendrame F, Verrienti A, Parlapiano C, Filetti S, Dotta F, Morano S. Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Ann Clin Biochem. 2008;45(Pt 2):218-20. doi: 10.1258/acb.2007.007117.

130. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J Endocrinol Invest. 2007;30(10):RC31-4.

131. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab. 2008;93(3):910-3.

132. Scipioni A, Ferretti E, Soda G, Tosi E, Bruno R, Costante G, Meringolo D, Arturi F, Durante C, Amorosi A, Foschini MP, Nardi F, Russo D, Filetti S. hNIS protein in thyroid: the iodine supply influences its expression and localization. Thyroid. 2007;17(7):613-8.

133. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007 ;92(7):2840-3.

134. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, Durante C, Maranghi M, Filetti S, Russo D. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. Thyroid. 2007;17(4):363-6.

135. Faggiano A, Caillou B, Lacroix L, Talbot M, Filetti S, Bidart JM, Schlumberger M. Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid. 2007;17(3):203-11.

136. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab. 2007;3(3):260-9.

137. Maranghi M, Coletta P, Durante C, Pergolini D, Filetti S. Cardiovascular disease and metabolic syndrome Recenti Prog Med. 2006;97(12):719-26.

138. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007 ;92(2):450-5.

139. Filetti S, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. Nat Clin Pract Endocrinol Metab. 2006;2(7):384-94.

140. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1(1):32-40.

141. Pines A, Bivi N, Vascotto C, Romanello M, D'Ambrosio C, Scaloni A, Damante G, Morisi R, Filetti S, Ferretti E, Quadrifoglio F, Tell G. Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway. J Cell Physiol. 2006;209(1):44-55.

142. Caliumi C, Cotesta D, Petramala L, Lorio M, Salvati M, Filetti S, De Toma G, D'Erasmo E, Letizia C. An unusual association of cerebral meningioma, parathyroid adenoma and thyroid papillary carcinoma. Tumori. 2006;92(2):178-80.

143. Lacroix L, Michiels S, Mian C, Arturi F, Caillou B, Filetti S, Schlumberger M, Bidart JM. HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. Clin Endocrinol (Oxf). 2006;64(4):398-404.

144. D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S.Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(3):754-9

http://www.ncbi.nlm.nih.gov/pubmed/18434729http://www.ncbi.nlm.nih.gov/pubmed/18434729


145. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciante V, Di Giorgio A, Bruno R, Filetti S, Trischitta V. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab. 2006;91(1):60-3.

146. Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, Filetti S, Russo D. Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab. 2005;90(10):5692-7.

147. Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, Scipioni A, Celano M, Gulino A, Filetti S, Russo D. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer. 2005 19;5:80.

148. Ferretti E, Arturi F, Mattei T, Scipioni A, Tell G, Tosi E, Presta I, Morisi R, Lacroix L, Gulino A, Russo D, Damante G, Filetti S. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines. Endocrinology. 2005;146(9):4009-15.

149. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei T, Pianta A, Pellizzari L, Damante G. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology. 2005 ;146(9):3967-74.

150. Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, Presta I, Bulotta S, Ferretti E, Filetti S, Scaloni A, Damante G, Tell G. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J Endocrinol Invest. 2005;28(2):137-44.

151. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005 ;152(1):1-9.

152. Scarpelli D, D'Aloiso L, Arturi F, Scillitani A, Presta I, Bisceglia M, Cristofaro C, Russo D, Filetti S. Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. J Endocrinol Invest. 2004;27(11):1015-21.

153. Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, Filetti S, Schlumberger M. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest. 2004;27(11):1010-4.

154. Arturi F, Ferretti E, Presta I, Mattei T, Scipioni A, Scarpelli D, Bruno R, Lacroix L, Tosi E, Gulino A, Russo D, Filetti S. Regulation of iodide uptake and sodium/iodide symporter expression in the mcf-7 human breast cancer cell line. J Clin Endocrinol Metab. 2005;90(4):2321-6.

155. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroti D, Filetti S, Fresta M, Russo D. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer. 2004;4:63.

156. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzò G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89(7):3402-7.

157. Tell G, Pines A, Arturi F, Cesaratto L, Adamson E, Puppin C, Presta I, Russo D, Filetti S, Damante G. Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells. Endocrinology. 2004;145(10):4660-6.

158. Romeo S, Menzaghi C, Bruno R, Sentinelli F, Fallarino M, Fioretti F, Filetti S, Balsamo A, Di Mario U, Baroni MG. Search for genetic variants in the retinoid X receptor-gamma-gene by polymerase chain reaction-single-strand conformation polymorphism in patients with resistance to thyroid hormone without mutations in thyroid hormone receptor beta gene. Thyroid. 2004;14(5):355-8.

159. Torrente I, Arturi F, D'Aloiso L, Colosimo A, De Luca A, Ferretti E, Russo D,Chiefari E, Scarpelli D, Bisceglia M, Dallapiccola B, Filetti S. Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma. J Endocrinol Invest. 2004;27(2):111-6.

160. Corsetti F, Chianelli M, Cornelissen B, Van de Wiele C, D'Alessandria C, Slegers G, Mather SJ, Di Mario U, Filetti S, Scopinaro F, Signore A. Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. Cancer Biother Radiopharm. 2004;19(1):57-63.

161. Puppin C, Presta I, D'Elia AV, Tell G, Arturi F, Russo D, Filetti S, Damante G. Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. Mol Cell Endocrinol. 2004;214(1-2):117-25.

162. Costante G, Crocetti U, Schifino E, Ludovico O, Capula C, Nicotera M, Arturi F, Filetti S. Slow growth of benign thyroid nodules after menopause: no need for long-term thyroxine suppressive therapy in post-menopausal women. J Endocrinol Invest. 2004;27(1):31-6.

163. Puppin C, Arturi F, Ferretti E, Russo D, Sacco R, Tell G, Damante G, Filetti S. Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1. Endocrinology. 2004;145(3):1290-3.

164. Arturi F, Scarpelli D, Coco A, Sacco R, Bruno R, Filetti S, Russo D. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid. 2003;13(4):341-3.

165. Celano M, Arturi F, Presta I, Bruno R, Scarpelli D, Calvagno MG, Cristofaro C, Bulotta S, Giannasio P, Sacco R, Filetti S, Russo D. Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol Cell Endocrinol. 2003;203(1-2):129-35

166. Puppin C, D'Elia AV, Pellizzari L, Russo D, Arturi F, Presta I, Filetti S, Bogue CW, Denson LA, Damante G. Thyroid-specific transcription factors control Hex promoter activity. Nucleic Acids Res. 2003;31(7):1845-52.

167. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 2003;148(1):19-24.

168. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer. 2002 Dec 10;2:35.

169. Arturi F, Presta I, Scarpelli D, Bidart JM, Schlumberger M, Filetti S, Russo D. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression. Eur J Endocrinol. 2002 Nov;147(5):655-61.

170. Russo D, Celano M, Bulotta S, Bruno R, Arturi F, Giannasio P, Filetti S, Damante G, Tell G. APE/Ref-1 is increased in nuclear fractions of human thyroid hyperfunctioning nodules. Mol Cell Endocrinol. 2002 Aug 30;194(1-2):71-6.

171. Arturi F, Chiefari E, Tumino S, Russo D, Squatrito S, Chazenbalk G, Persani L, Rapoport B, Filetti S.


Similarities and differences in the phenotype of members of an Italian family with hereditary non-autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation. J Endocrinol Invest. 2002 Sep;25(8):696-701.

172. Giardina E, Capon F, D'Apice MR, Amati F, Arturi F, Filetti S, Bonifazi E, Pucci S, Conte C, Novelli G. Mutational analysis of Peroxiredoxin IV: exclusion of a positional candidate for multinodular goitre. BMC Med Genet. 2002 Jul 23;3:5.

173. Arturi F, Lacroix L, Presta I, Scarpelli D, Caillou B, Schlumberger M, Russo D, Bidart JM, Filetti S. Regulation by human chorionic gonadotropin of sodium/iodide symporter gene expression in the JAr human choriocarcinoma cell line. Endocrinology. 2002 Jun;143(6):2216-20.

174. Costante G, Grasso L, Schifino E, Marasco MF, Crocetti U, Capula C, Chiarella R, Ludovico O, Nocera M, Parlato G, Filetti S. Iodine deficiency in Calabria: characterization of endemic goiter and analysis of different indicators of iodine status region-wide. J Endocrinol Invest. 2002 Mar;25(3):201-7.

175. Lombardo F, Baudin E, Chiefari E, Arturi F, Bardet S, Caillou B, Conte C, Dallapiccola B, Giuffrida D, Bidart JM, Schlumberger M, Filetti S. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab. 2002 Apr;87(4):1674-80.

176. Belfiore A, Russo D, Vigneri R, Filetti S. Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf). 2001 Dec;55(6):711-8.

177. D'Elia AV, Tell G, Russo D, Arturi F, Puglisi F, Manfioletti G, Gattei V, Mack DL, Cataldi P, Filetti S, Di Loreto C, Damante G. Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors. J Clin Endocrinol Metab. 2002 Mar;87(3):1376-83.

178. Biondi B, Palmieri EA, Filetti S, Lombardi G, Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. Lancet. 2002 Mar 2;359(9308):799-800.

179. Boland A, Magnon C, Filetti S, Bidart JM, Schlumberger M, Yeh P, Perricaudet M. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid. 2002 Jan;12(1):19-26.

180. Lacroix L, Nocera M, Mian C, Caillou B, Virion A, Dupuy C, Filetti S, Bidart JM, Schlumberger M. Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. Thyroid. 2001 Nov;11(11):1017-23.

181. Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, Bidart JM, Schlumberger M, Filetti S. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol. 2001 Nov;145(5):591-7.

182. Mian C, Lacroix L, Bidart JM, Caillou B, Filetti S, Schlumberger M. Sodium/iodide symporter in thyroid cancer. Exp Clin Endocrinol Diabetes. 2001;109(1):47-51.

183. Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol. 2001;145(2):129-35.

184. Russo D, Arturi F, Bulotta S, Pellizzari L, Filetti S, Manzini G, Damante G, Tell G. ApeI/Ref-I expression and cellular localization in human thyroid carcinoma cell lines. J Endocrinol Invest. 2001;24(3):RC10-2.

185. Chiefari E, Chiarella R, Crocetti U, Tardio B, Arturi F, Russo D, Trischitta V, Filetti S, Zingrillo M. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC. Horm Metab Res. 2001; 33(1):52-6.

186. Lombardo F, Filetti S, Crocetti U, Schlumberger M. Medullary thyroid carcinoma and lack of renal agenesis. Thyroid 2001;11(1):93.

187. Russo D, Manole D, Arturi F, Suarez HG, Schlumberger M, Filetti S, Derwahl M.Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. Thyroid. 2001;11(1):37-9.

188. Lacroix L, Mian C, Caillou B, Talbot M, Filetti S, Schlumberger M, Bidart JM. Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol. 2001;144(3):297-302.

189. Orlandi F, Chiefari E, Caraci P, Mussa A, Gonza

FORMATO EUROPEO PER IL CURRICULUM VITAE...ricerca di circa 40 studi clinici negli ultimi anni....

Documents

Transcript of FORMATO EUROPEO PER IL CURRICULUM VITAE...ricerca di circa 40 studi clinici negli ultimi anni....